Australian Parliament passes historic medicinal cannabis legislation

24 February 2016
cannabis

Australia’s Parliament has today passed the Turnbull Government’s historic legislation delivering the “missing piece” for Australian patients and their doctors to access a safe, legal and reliable supply of medicinal cannabis products for the management of painful and chronic conditions.

Minister for Health Sussan Ley today thanked her Parliamentary colleagues from across both Chambers and the political spectrum for the fast passage of the Government’s legislation in a bi-partisan fashion.

“This is an historic day for Australia and the many advocates who have fought long and hard to challenge the stigma around medicinal cannabis products so genuine patients are no longer treated as criminals,” Ms Ley said, adding: “This is the missing piece in a patient’s treatment journey and will now see seamless access to locally-produced medicinal cannabis products from farm to pharmacy….Today's outcome is a demonstration of this Parliament's commitment to not only ensure we get access to a safe, legal and reliable supply of medicinal cannabis products for Australian patients, but we also get it right.”

Provides a pathway for legally-grown cannabis for the first time

Today’s passing of amendments to the Narcotic Drugs Act will, for the first time, provide a pathway of legally-grown cannabis for the manufacture of suitable medicinal cannabis products in Australia.

“A national regulator will allow the government to closely track the development of cannabis products for medicinal use from cultivation to supply and curtail any attempts by criminals to get involved,” Ms Ley said.

Under this scheme, a patient with a valid prescription can possess and use a medicinal cannabis product manufactured from cannabis plants legally cultivated in Australia, where the supply is appropriately authorised under the Therapeutic Goods Act 1989 and relevant state and territory legislation.

To support this, Ms Ley also announced the Department of Health, in conjunction with the Therapeutic Goods Administration (TGA), was currently well-advanced in having cannabis for medicinal purposes considered for down-scheduling to Schedule 8 of the Poisons Schedule. The TGA undertook public consultation on down-scheduling cannabis for medicinal purposes in January 2016, with an interim decision due in March 2016. Further consultation will then follow.

Ms Ley also announced an independent Advisory Committee would be established to oversee the next stage of the rollout of the national regulator now legislation has passed. She reminded Australians today’s announcement did not relate to the decriminalization of cannabis for general cultivation or recreational use, which remained a law enforcement issue for individual states and territories.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical